-- Founded by Barbara Ehrlich, Ph.D. at Yale University
-- Bob Linke appointed Chief Executive Officer
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.
Osmol was founded by Dr. Barbara Ehrlich, Professor of Pharmacology and of Cellular and Molecular Physiology, Yale School of Medicine. Her research on neuronal calcium sensor-1 (NCS1), a critical calcium binding protein that regulates intracellular calcium levels, forms the basis of Osmols CIPN treatment, OSM-0205 and future potential NCS1 therapeutics. OSM-0205s mechanism addresses the off-target toxicity of microtubule-based chemotherapy agents that results in a calcium surge leading to CIPN. OSM-0205 modulates NCS1 to prevent the calcium surge and maintain neuronal integrity.
The companys initial focus is CIPN in breast cancer patients resulting from taxane-based chemotherapy treatment. Taxanes are the most widely used chemotherapy treatment for breast cancer and can lead to CIPN in up to 80% of patients. Independent market research conducted with breast cancer oncologists at leading US cancer centers confirmed that CIPN is the most significant toxicity issue facing clinicians and patients when treating breast cancer.
Chemotherapy-induced peripheral neuropathy is a devastating adverse event that can leave patients and their treating physicians with a very difficult choice reduce taxane therapy with the possibility of negatively impacting patient outcomes or continue therapy at the recommended dose with the potential of causing increased and possibly permanent, disabling CIPN, said Dr. Ehrlich. OSM-0205 is being developed with the goal of preventing CIPN before it occurs. By blocking the calcium surge that causes neuropathy, optimal treatment with taxanes can continue. This is particularly important in the treatment of breast cancer where taxanes remain the foundation of most therapeutic regimens.
There are currently no FDA-approved therapies to avoid or reduce CIPN, creating an urgent need for patients being treated with chemotherapy, said Robert Berman, M.D., Executive Chairman of Osmol Therapeutics and co-founder and former Chief Medical Officer at Biohaven Pharmaceuticals. Over 225,000 patients in the U.S. and the European Union with early stage or metastatic breast cancer are treated with taxanes each year. We have recruited an experienced and capable executive team, led by Bob Linke, Osmols Chief Executive Officer, to advance OSM-0205 to address this need as well as explore the potential use of neuronal calcium sensor-1 (NCS1) in other indications. We are excited by the potential of OSM-0205 and expect to begin clinical development as early as next year.
Bob Linke, MBA, is an experienced biopharma entrepreneur, who is also Executive Chairman of Embera NeuroTherapeutics and IonSense. He has an established track record developing strategies, building and leading emerging companies through all phases of growth from research, product development and clinical studies to successful commercialization, partnership and acquisitions. Bob brings an open management style to create cohesive, high-functioning teams. He has raised over $70 million in private equity and non-dilutive financing to fund these companies development and commercialization efforts. His early career was spent at Baxter, developing and commercializing pharmaceuticals and drug delivery systems.
About OSM-0205 and CIPN
Osmols lead drug, OSM-0205, is based on Dr. Barbara Ehrlichs research in neuronal calcium sensor-1 (NCS1) at Yale University and is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage. Data from preclinical studies conducted by Osmol show that pre-treatment with OSM-0205 prevents neuronal damage from taxanes in mice by preventing the off-target intracellular calcium surge caused by these chemotherapy agents. It is hypothesized that OSM-0205 modulates NCS1 in patients to protect neurons from damage leading to a reduction of CIPN. CIPN affects hundreds of thousands of cancer patients every year and can compromise optimum chemotherapy dosing. There are no effective treatments for CIPN, a condition which can diminish quality of life and lead to lifelong disability.
About Osmol Therapeutics
Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN) based on the ground-breaking work of Dr. Barbara Ehrlich on the role of NCS1 in calcium signaling and regulation in preventing nerve damage associated with chemotherapy. The companys lead indication will be for the prevention of CIPN in breast cancer patients treated with taxane-based therapy, a treatment regimen in which up to 80% of patients experience CIPN. For more information, please go to https://osmoltherapeutics.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005224/en/
Continue reading here:
Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy - BioSpace
- Peripheral neuropathy: Causes, symptoms, treatment, and prevention - September 21st, 2024
- Sponsored: Say goodbye to neuropathy with help from NexGenEsis Healthcare - KHOU.com - September 21st, 2024
- Danish Study Reveals Connection Between Diabetic Neuropathy, Retinopathy, and Severe Periodontitis - Medical Dialogues - September 21st, 2024
- What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And ... - Forbes - July 30th, 2024
- Neuropathy | Duke Health - October 16th, 2023
- Peripheral Neuropathy | University Hospitals - May 9th, 2023
- Cranial Neuropathies | University Hospitals - May 9th, 2023
- Treatment for Peripheral Neuropathy & Other Nerve Damage | University ... - May 9th, 2023
- Neuromuscular Disease | Facts About Neuromuscular Disorders, Symptoms ... - May 9th, 2023
- Patrick McIntyre MD, JD Doctor Profile & Reviews | University Hospitals - May 9th, 2023
- Peripheral Neuropathy: What It Is, Symptoms & Treatment - Cleveland Clinic - May 1st, 2023
- Peripheral Neuropathy | National Institute of Neurological Disorders ... - May 1st, 2023
- Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study... - May 1st, 2023
- Successfully Treating Diabetic Neuropathy at Vero Neuropathy | Paid Content - Local 5 - weareiowa.com - May 1st, 2023
- Peripheral Neuropathy Treatment at Advanced Nerve and Health Center - WFAA.com - May 1st, 2023
- Different Types of Peripheral Neuropathy | Paid Content - Local 5 - weareiowa.com - February 24th, 2023
- Peripheral neuropathy: Symptoms, causes, and treatment - Medical News Today - February 24th, 2023
- Natural Treatments for Peripheral Neuropathy - Healthline - December 28th, 2022
- Diabetic neuropathy types: Symptoms tell the story - Mayo Clinic - December 28th, 2022
- Supplements for Neuropathy: Vitamins and More - Healthline - December 28th, 2022
- The Effectiveness of Topical Cannabidiol Oil in Symptomatic ... - PubMed - December 28th, 2022
- Autonomic neuropathy - Diagnosis and treatment - Mayo Clinic - December 28th, 2022
- Peripheral neuropathy - Causes - NHS - December 28th, 2022
- Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and ... - PubMed - December 28th, 2022
- What Is Auditory Neuropathy? Causes & Treatment | NIDCD - December 20th, 2022
- Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content - Local 5 - weareiowa.com - December 20th, 2022
- Neuropathy No More Reviews (Blue Heron Health News) Does It Work? - Outlook India - December 20th, 2022
- Neuropathy Pain Treatment Market Size to Grow by USD 3.81 Bn, Growing Focus on Emerging Economies to be a Key Trend - Technavio - Yahoo Finance - October 7th, 2022
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 7th, 2022
- Anti-hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin-induced diabetic neuropathy imply MAPK pathway and calcium dynamics... - October 7th, 2022
- Side effects that may arise during breast cancer treatment The Hamburg Reporter - Hamburg Reporter - October 7th, 2022
- Neuropathy & the Truth About Alternative Care - North Forty News - June 16th, 2022
- Chemotherapy-Induced Peripheral Neuropathy: The Invisible Side Effect - Curetoday.com - June 16th, 2022
- Thermal gradient ring reveals thermosensory changes in diabetic peripheral neuropathy in mice | Scientific Reports - Nature.com - June 16th, 2022
- GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022 - Business Wire - June 16th, 2022
- Warning Signs of Diabetes, Says Physician Eat This Not That - Eat This, Not That - June 16th, 2022
- Foot Disease: The Most Feared Of All The Consequences Of Diabetes - Pressat - June 16th, 2022
- How Mindfulness Meditation May Help Ease Stress and Anxiety in Cancer Survivors, and Where to Start - Curetoday.com - June 16th, 2022
- TYPES OF CANNABIS STRAINS AND THE TYPE OF PAIN THEY TREAT - GISuser.com - June 16th, 2022
- 5 Types of Neuropathy and What to Do About Them | Fort ... - April 26th, 2022
- Unilateral Compressive Optic Neuropathy As the Presenting Manifestation of Clival Chordoma: A Case Report - Cureus - April 26th, 2022
- A Case of Secondary Trigeminal Neuropathy Due to Local Malignant Invasion of the Maxillary and Mandibular Nerves at the Skull Base: A Case Report With... - April 26th, 2022
- Global Leber's Hereditary Optic Neuropathy Drug Market 2022 to 2031 Analysis themobility.club - themobility.club - April 26th, 2022
- Risks of vitamin B12 deficiency and the symptoms to look out for - My London - April 26th, 2022
- NeuraLace announces two new patents for Axon neuropathic pain therapies - NeuroNews International - April 26th, 2022
- Neuropathic pain Market Overview By Share, Size, Industry Players, Revenue and Product Demand 2021-2030 The New York Irish Emgirant - The New York... - April 26th, 2022
- Find Help For Peripheral Neuropathy With Corrective Health - KXAN.com - November 21st, 2021
- AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022 - Business Wire - November 21st, 2021
- Diabetic Neuropathy Treatment Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Northwest Diamond Notes - November 21st, 2021
- Diabetes: The 'tingling' sensation that can be caused by long-term high blood sugar - Daily Express - November 21st, 2021
- Vaccinations urged against shingles, a viral infection that's on the rise - Yahoo News - November 21st, 2021
- Broadway Vascular Announces Top-Line Results of 12-Month Retrospective Analysis Evaluating Revascularization of the Lateral Plantar Artery in Diabetic... - October 26th, 2021
- Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency - Yahoo Finance - October 26th, 2021
- Heres Why Alger Sold its Nevro Corp. (NVRO) Position - Yahoo Finance - October 26th, 2021
- Zika virus in UP: Symptoms, treatment and other things to know - Hindustan Times - October 26th, 2021
- Ask the GP: Why do my feet feel like they're on fire? - The Irish News - October 26th, 2021
- For veterans: VA prepares to tackle backlogged disability claims - The Herald-Times - October 26th, 2021
- Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help... - August 17th, 2021
- Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy - BioSpace - August 17th, 2021
- CCM can identify nerve damage in patients with long COVID, new study finds - Mobihealth News - August 17th, 2021
- Spotlight on ultrasonography in the diagnosis of PND | IJGM - Dove Medical Press - August 17th, 2021
- Eye scan could determine whether COVID patients will be long haulers - WGNO New Orleans - August 17th, 2021
- Diabetic Neuropathy Treatment Market Trends and Forecast to 2027 Players are Abbott, Roche, Eli Lilly - The Manomet Current - August 17th, 2021
- The Feather and the Knife: Navigating Life With Chronic Pain - POZ - August 17th, 2021
- Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing - Yahoo Finance - August 17th, 2021
- Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Yahoo Finance - August 17th, 2021
- Ugly Side Effects of Too Many Vitamins - Eat This Not That - Eat This, Not That - August 17th, 2021
- Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain - Digital... - May 14th, 2021
- Global Chronic Pain associated with Painful Diabetic Neuropathy Market to 2025 - Insight, Competitive Landscape and Forecasts - ResearchAndMarkets.com... - May 14th, 2021
- Leber's Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Will Accelerate at a CAGR Through 2021-2027 | Rising Technological Innovations... - May 14th, 2021
- Chemotherapy induced peripheral neuropathy Pipeline Insight to See Strong Expansion Through 2027 Covid-19 Analysis The Courier - The Courier - May 14th, 2021
- Diabetic Retinopathy Market Size Growth Expects Significant Thrust at a CAGR of 3% During the Study Period, 2018-30 in the 7MM | DelveInsight -... - May 14th, 2021
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19 - Business Wire - May 14th, 2021
- Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2... - May 14th, 2021
- Phenotypic Stratification of Patients With Painful Neuropathy May Predict Response to Therapy - Clinical Pain Advisor - May 2nd, 2021
- Peripheral Neuropathy Treatment Market: Development, Growth, Trends, Demand, Analysis and Forecast 2026 KSU | The Sentinel Newspaper - KSU | The... - May 2nd, 2021
- Diabetic Neuropathy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 The Courier - The Courier - May 2nd, 2021
- Leber's Hereditary Optic Neuropathy Drug Market Size and Forecast 2027 | Top Key Players Alkeus Pharmaceuticals, Ixchel Pharma, LLC, Biovista Inc.,... - May 2nd, 2021
- There are treatment options for neuropathy | News, Sports, Jobs - SalemNews.net - March 3rd, 2021
- Global Optic Neuropathy Drug Market: Industry Analysis and Forecast (2021-2028) By Products, Application, End-uses, and Region. KSU | The Sentinel... - March 3rd, 2021